top of page

First-in-Canada testing program for Alzheimer’s

On July 1, 2021 the St. Paul's Hospital Clinical Laboratory in Vancouver launched the Alzheimer's disease biomarker testing program for all Canadians.

Read the story here:

This first-in-Canada program was made possible via the IMPACT-AD study. The IMPACT-AD British Columbia and IMPACT-AD Canada studies were launched to help Canadians develop a comprehensive understanding of how Alzheimer’s disease biomarker testing impacts medical and personal decision making, and health care costs. The goal of IMPACT-AD is to inform positive change in the Canadian health care system to improve care and support for individuals living with Alzheimer’s disease, and their families.


bottom of page